 |
|
|
|
 |
|
|
| Article 1 to 6 out of 6 concerning Theragenics Corporation
|
-
TheraGenetics Closes £3M Series A Financing
(11 Jul 2007)
Pursues Commercialisation of Pharmacogenetic Diagnostic Tests for PatientResponse Prediction in CNS Disorders
TheraGenetics Ltd announced the successful completion of a £3 million Series A venture financing round. Swarraton Partners led the financing with participation from Tudor Capital, IP Venture Fund, IP Group plc's venture capital fund which was raised ...
-
Theragenics acquires vascular access device manufacturer Galt Medical Corp.
(08 Aug 2006)
Theragenics Corporation(R) acquiered Galt Medical Corp. effective August 2, 2006. Galt, a privately held company, develops, manufactures and markets disposable medical devices utilized for vascular access, primarily serving the interventional ...
-
Theragenics Corporation(R) Restructures to Focus on Core Business Units
(15 Aug 2005)
Theragenics Corporation(R) announced a plan to restructure the Company to focus on its two main business sectors: the primary product line of brachytherapy seeds and its medical device product lines through its newly acquired subsidiary, CP Medical. ...
-
Theragenics Corporation Acquires CP Medical
(10 May 2005)
Theragenics Corporation(R) announced the acquisition of CP Medical, a medical device company, for approximately $19,150,000 in cash and 1,885,370 shares of Theragenics'(TM) common stock valued at approximately $6,250,000, for a total purchase price ...
-
Theragenics Corporation Agrees to Acquire CP Medical
(29 Apr 2005)
Theragenics Corporation(R) announced that it has entered into an agreement to acquire CP Medical, a medical device company. CP Medical is a manufacturer and supplier of innovative sutures, cardiac pacing cables, brachytherapy needles/spacers, and ...
-
New Peer-Reviewed Study Demonstrates Cure Rates of Brachytherapy with Palladium-103
(09 Mar 2005)
A new peer-reviewed study demonstrates that cure rates achieved with brachytherapy using palladium-103 are better than or equal to traditional surgery for treating prostate cancer. The twelve-year study proves the superior efficacy of brachytherapy, ...
|
|
|
|
|
Top
